|
|
Article: Micromet's BiTE(R) Antibodies Reveal Unique Mode of Action.
- Article from:
- PR Newswire
- Article date:
- November 6, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BETHESDA, Md., Nov. 6 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the publication of two new studies describing a unique mode of action of Micromet's bispecific BiTE antibody therapeutics. The studies were published in the Journal of Immunotherapy(1) and in Cancer Immunology Immunotherapy(2), respectively.
BiTE antibodies are designed to transiently connect cytotoxic T cells with cancer cells leading to a tightly controlled and serial elimination of cancer cells. In this process, cytotoxic T cells are activated, which ...